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Psoriasis is a chronic in¯ammatory skin disease in
which epidermal proliferation is closely associated
with excessive microvascular expansion within the
papillary dermis. Angiopoietins have recently been
identi®ed as the major ligands of the endothelial-
speci®c receptor Tie2. Angiopoietin 1 induces Tie2
signaling as a receptor activator and maintains blood
vessel formation, whereas angiopoietin 2 destabilizes
vessels by blocking Tie2 signaling as an antagonist of
angiopoietin 1 and acts with vascular endothelial
growth factor to initiate angiogenesis. In this study
we examined the potential role of angiopoietins and
the Tie2 receptor in vascular changes of psoriasis.
Angiopoietin 1, angiopoietin 2, and Tie2 were up-
regulated in involved psoriasis skin compared to
uninvolved psoriasis skin, healthy skin, and chronic
spongiotic dermatitis skin. Angiopoietin 1 was
expressed by stromal cells in the highly vascularized
papillary dermis of involved psoriasis skin.
Angiopoietin 2 was expressed by endothelial cells in
the vicinity of the proliferating epidermis that abun-
dantly expressed vascular endothelial growth factor.
Vascular endothelial growth factor and basic ®bro-
blast growth factor, which were overexpressed in
involved psoriasis skin, enhanced angiopoietin 2 and
Tie2 expression in dermal microvascular endothelial
cell cultures. Thus, our ®ndings suggest that upregu-
lation of angiopoietin 1, angiopoietin 2, and Tie2 is
closely associated with the development of micro-
vascular proliferation in psoriasis, and that the angio-
poietin±Tie2 system may act coordinately with
vascular endothelial growth factor and basic ®bro-
blast growth factor to promote neovascularization in
psoriasis. Moreover, successful antipsoriatic treat-
ment was accompanied by noticeable reduction of
angiopoietin 2 expression, suggesting that alteration
of angiopoietin 2 expression may be particularly
important in controlling vascular proliferation in the
treatment of psoriasis. Key words: angiogenesis/basic
®broblast growth factor/vascular endothelial growth factor.
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P
soriasis is a common, chronic skin disease characterized
by recurrent erythematous skin plaques that exhibit
epidermal hyperplasia, in¯ammatory cell accumulation,
and abnormalities of the papillary dermal vasculature
(Weinstein et al, 1985; Mordovtsev and Albanova, 1989;
Baker and Fry, 1992). Microvessels in the papillary dermis of
psoriatic plaques are tortuous and dilated (Ragaz and Ackerman,
1979), show increased endothelial surface areas (Macdonald et al,
1989), and exhibit endothelial cell proliferation (Braverman and
Sibley, 1982; Morganroth et al, 1991). In vivo angiogenesis assays
have demonstrated the ability of the lesional epidermis to induce
neovascularization (Malhotra et al, 1989). Furthermore, over-
expression of strong angiogenic inducers, such as vascular
endothelial growth factor (VEGF) and basic ®broblast growth
factor (bFGF), has also been demonstrated in psoriasis (Yaguchi et
al, 1993; Detmar et al, 1994).
Recently, angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) were
identi®ed as ligands of the Tie2 (Tek) receptor, a novel
endothelium speci®c receptor tyrosine kinase (Sato et al, 1995;
Davis et al, 1996; Suri et al, 1996; Maisonpierre et al, 1997). Ang1
induces Tie2 autophosphorylation as a receptor activator, whereas
Ang2 blocks Tie2 signaling as a naturally occurring antagonist of
Ang1.
Ang1±Tie2 signaling is essential for correct vascular formation.
Mouse embryos lacking either Ang1 or Tie2 show the absence of
capillary sprouts and abnormal vascular networks, leading to
embryo lethality (Dumont et al, 1994; Sato et al, 1995; Suri et al,
1996). Ultrastructural analyses in Ang1 knockout mice demon-
strated the loss of adhesion between endothelial cells and associated
pericytes (Suri et al, 1996). This suggests that Ang1±Tie2 signaling
helps maintain and stabilize newly formed vessels by regulating the
interaction between endothelial cells and surrounding support cells,
such as smooth muscle cells and pericytes (Suri et al, 1996).
Furthermore, Ang1 may act directly on endothelial cells as an
effective apoptosis survival factor (Kwak et al, 1999). In addition,
Ang1 has a crucial function in vascular expansion as Ang1
overexpression in mouse skin results in increased vascularity (Suri
et al, 1998). In vitro experiments demonstrated that Ang1 induced
only weak proliferation in endothelial cells, but strongly supported
sprouting (Davis et al, 1996; Koblizek et al, 1998) and chemotactic
responses (Witzenbichler et al, 1998).
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In contrast, Ang2 promotes vessel destabilization by blocking the
Ang1±Tie2 receptor interaction. Transgenic overexpression of
Ang2 leads to a lethal phenotype reminiscent of embryos lacking
either Ang1 or Tie2, with severe disruption of vascular develop-
ment (Maisonpierre et al, 1997). During embryogenesis, Ang2 has
been demonstrated primarily at sites of vascular remolding. Ang2 is
expressed together with VEGF at the invading front of vessel
sprouting, or in the absence of VEGF at sites of vessel regression
(Maisonpierre et al, 1997). These expression patterns suggest that
vessel destabilization by Ang2 in the absence of VEGF leads to
frank vascular regression, whereas such destabilization in the
presence of angiogenic inducers such as VEGF strongly facilitates
angiogenic responses. Recently, it has been shown that the
sequential and cooperative expression of Ang2 and VEGF is
essential in tumor angiogenesis (Stratmann et al, 1998; Holash et al,
1999). Thus, these ®ndings indicate that Ang2 is a crucial factor in
the initiation of angiogenesis and that Ang2 and VEGF have
distinct yet complementary roles in vascular development.
To elucidate the potential role of the angiopoietin/Tie2 system
in vascular changes of psoriasis, we examined the expression and
localization of Ang1, Ang2, and Tie2 in psoriasis skin and studied
the cytokine-mediated regulation of these molecules in cell
cultures.
MATERIALS AND METHODS
Skin specimens Six millimeter punch biopsies from clinically
uninvolved and involved skin of 14 different patients with untreated,
chronic plaque-type psoriasis were obtained according to a protocol
approved by the Institute Review Board of Mount Sinai School of
Medicine. Patients ranged in age from 36 to 54 y. Skin biopsies were
divided in two and used for histopathologic examination and reverse
transcriptase polymerase chain reaction (RT-PCR) analysis. Gene
expression during antipsoriatic therapy was analyzed for seven patients, of
whom ®ve received psoralen plus ultraviolet A light (PUVA) treatment
and two received topical tazarotene (a retinoid acid receptor b/g
selective retinoid) treatment as described previously (Hecker et al, 1999).
Normal adult skins obtained from reconstructive surgery were used as
healthy controls. In addition, punch biopsies from four untreated patients
with chronic spongiotic dermatitis were included in this study.
Cell cultures Human microvascular endothelial cells of dermal origin
(HMVEC) were purchased from Clonetics (San Diego, CA) and were
grown in endothelial cell basal medium (EBM, Clonetics) containing
human epidermal growth factor (10 ng per ml), hydrocortisone (1 mg per
ml), 5% fetal bovine serum (FBS), and bovine brain extract (12 mg per
ml). HMVECs were used between passages 4 and 6. Human dermal
®broblasts were derived by explant outgrowth from normal adult skins as
described previously (Kuroda et al, 1999) and cultured in Dulbecco's
modi®ed Eagle's medium (DMEM) supplemented with 2 mM glutamine
and 10% FBS. Fibroblasts at four to seven passages were used for
experiments. Human recombinant VEGF were purchased from R&D
systems (Minneapolis, MN). Human recombinant bFGF, platelet-derived
growth factor (PDGF), and transforming growth factor b1 (TGF-b1)
were from Roche Molecular Biochemicals (Indianapolis, IN).
RNA preparation and cDNA synthesis Total RNA from skin
specimens and cell cultures was isolated using the RNeasy kit (Qiagen,
Chatsworth, CA). After deoxyribonuclease I treatment (Life
Technologies, Grand Island, NY), total RNA was reverse transcribed
into cDNA for PCR ampli®cation using oligo(dT) primer and Molony
murine leukemia virus reverse transcriptase (Life Technologies).
Quantitative RT-PCR Competitive RT-PCR was performed by
mixing a constant amount of the target cDNA with varying copy
numbers of competitive DNA fragments. Target cDNA was ampli®ed
with known amounts of competitor in 50 ml reaction mixtures
containing 1 3 PCR buffer, 200 nM dNTP, 1.5 mM MgCl2, 500 nM
primers, and 1.25 U Platinum Taq DNA polymerase (Life
Technologies). Cycling parameters were as follows: denaturation, 94°C
for 30 s; annealing, 60°C (for VEGF and bFGF) or 65°C (for all other
molecules) for 1 min; extension, 72°C for 1 min, with 30±40 cycles.
Competitive DNA fragments were designed to contain the same primer
binding sequences as the target cDNA for each primer set and were
constructed using the competitive DNA construction kit (Takara
Biomedicals, Kusatu, Japan) according to the manufacturer's instructions.
As the ratios of target to competitor PCR product ampli®cations were
proven constant from 20 to 40 cycles in preliminary experiments, target
cDNAs and competitive fragments were con®rmed to be ampli®ed with
equal ef®cacy. The following primers were used for DNA ampli®cation:
Ang1, 5¢-GGGGGAGGTTGGACTGTAAT-3¢ and 5¢-AGGGCACAT-
TTGCACATACA-3¢ (362 bp PCR product); Ang2, 5¢-GGATCT-
GGGGAGAGAGGAAC-3¢ and 5¢-CTCTGCACCGAGTCATCGTA-
3¢ (535 bp); Tie2, 5¢- ATCCCATTTGCAAAGCTTCTGGCTGGC-3¢
and 5¢-TGTGAAGCGTCTCACAGGTCCAGGATG-3¢ (512 bp);
VEGF, 5¢-TCCAGGAGTACCCTGATGAG-3¢ and 5¢-TTCACATTT-
GTTGTG CTGT-3¢ (203 bp); bFGF, 5¢-CCAAGCGGCTGTACT-
GCAAA-3¢ and 5¢-TCCTTGACCGGTAAGTATTG-3¢ (270 bp);
platelet-endothelial cell adhesion molecule 1 (PECAM), 5¢-CTGAGG-
GTGAAGGTGATAGC-3¢ and 5¢-AGTATTTTGCTTCTGGGGAC-3¢
(296 bp); b-actin, 5¢-GTGATGGTGGGCATGGGTCA-3¢ and 5¢-TTA-
ATGTCACGCACGATTTCCC-3¢ (510 bp). All primer sets were tested
to ensure genomic DNA was not ampli®ed under the conditions used.
PCR products were electrophoresed in 3% agarose gels, visualized by
ethidium bromide staining, and photographed with Polaroid 665 ®lm.
Band intensities were then quanti®ed by densitometry (NIH Image 1.55
Program, National Institutes of Health, Division of Computer Research
and Technology, Bethesda, MD). To determine the number of
competitor template molecules equal to the starting number of the target
cDNA molecules, the ratios of the band intensities of target and
respective serially diluted competitor PCR products were plotted against
the starting number of competitor molecules. The copy numbers of
target cDNA were then calculated from the graph. The results are
presented as the number of transcripts per mg total RNA and are
normalized with respective b-actin ampli®cations.
Immunohistochemical staining Seven micron frozen sections were
®xed in 4% paraformaldehyde for 10 min and incubated with primary
antibody overnight at 4°C. The following antibodies were used for
detection: anti-Ang1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
Ang2 (Santa Cruz Biotechnology), anti-Tie2 (Santa Cruz
Biotechnology), anti-PECAM (Chemicon, Temecula, CA), anti-type IV
collagen a1 chain (a generous gift from Dr. Y. Sado, Division of
Immunology, Shigei Medical Research Institute), anti-a-smooth muscle
actin (aSMA) (Sigma, Saint Louis, MO), and anti-VEGF (Santa Cruz
Biotechnology). Biotinylated secondary antibodies and streptavidin-
peroxidase or -alkaline phosphatase conjugates (Vector Laboratories,
Burlingame, CA) were used to detect primary antibodies. Reactions
were developed using diaminobenzidine (DAB) or Fast Red (Zymed
Laboratories, South San Francisco, CA) as chromogenic substrates, and
some sections were counterstained with hematoxylin. Controls included
omission of the primary and/or secondary antibodies and preincubation
of Ang1, Ang2, and Tie2 antibodies with respective immunizing
peptides (Santa Cruz Biotechnology).
In situ hybridization For the preparation of Ang1 and Ang2 RNA
probes, T7 RNA polymerase promoters were incorporated into the
antisense and sense primers. RT-PCR was performed using one primer
with T7 RNA polymerase promoter and the unmodi®ed primer of the
pair (Birk and Grimm, 1994). Labeled probes were synthesized by in vitro
transcription with T7 polymerase in the presence of digoxigenin labeled
dUTP (Roche) using the PCR products as a template. Para-
formaldehyde-®xed, paraf®n-embedded specimens were used for in situ
hybridization. Sample pretreatment and hybridization was performed as
described previously (Kuroda et al, 1998) with some modi®cations.
Brie¯y, the deparaf®ned sections were incubated with proteinase K,
re®xed in 4% paraformaldehyde, incubated with glycine, and dipped in
0.2 N HCl. After prehybridization, sections were hybridized with
antisense or sense RNA probes in a solution containing 50% formamide,
10% dextran sulfate, 1 3 Denhardt's solution, 200 mg per ml yeast
tRNA, 600 mM NaCl, 1 mM ethylenediamine tetraacetic acid, 0.25%
sodim dodecyl sulfate (SDS), and 10 mM Tris-HCl (pH 7.6), and
incubated for 18 h at 50°C. Sections were washed in 2 3 sodium
citrate/chloride buffer (SSC), treated with RNAase A, and washed with
0.2 3 SSC at 50°C. Immunologic detection was performed with
antidigoxigenin antibody conjugated with alkaline phosphatase (Roche).
5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/
NBT) was used as chromogenic substrate.
Northern blot analysis An aliquot of total RNA (5 mg per lane) was
size fractionated by 1% agarose gel electrophoresis and transferred to a
nylon ®lter. Blots were prehybridized, hybridized, autoradiographed, and
stripped for rehybridization as previously described (Kuroda and Shinkai,
1997). Ang2 and Tie2 human cDNA probes used for hybridization were
prepared by RT-PCR as described above using total RNA isolated from
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human placenta (Clontech Laboratory, Palo Alto, CA) and were labeled
radioactive by nick translation kit with [a-32P]dCTP (Amersham
Pharmacia Biotech, Piscataway, NJ). As a control of constitutive
expression, a 0.8 kb human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA was used. The intensities of speci®c mRNAs were
quanti®ed with densitometry.
Immunoblotting analysis Protein extracts from cultured cells were
prepared using lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
and 1% Nonidet P-40). Equal amounts of the protein extracts were
separated on SDS-polyacrylamide gels under reducing conditions. For
cell culture media, proteins were precipitated by the addition of
trichloroacetic acid, and samples corresponding to the same cell numbers
were electrophoresed. Proteins were transferred to polyvinylidene
¯uoride membranes, detected by incubation with anti-Ang2 or Tie2
polyclonal antibodies (Santa Cruz Biotechnology), and visualized by the
enhanced chemi¯uorescence detection system (Amersham Pharmacia).
Relative protein levels were quanti®ed by densitometry.
Statistics The Mann±Whitney U test was used to compare gene
expression in skin samples from psoriasis patients and healthy controls.
Cytokine regulation in cell cultures was analyzed using the Student's t
test. Changes in gene expression before and during therapy were
analyzed by the Wilcoxon single-rank test. p-values of less than 0.05
were considered as signi®cant. All values were represented as mean
6 SD.
Figure 1. Increased expression of Ang1
mRNA in involved psoriasis skin. Total RNAs
from involved and uninvolved skin samples of 12
patients with psoriasis and seven healthy skin
samples were analyzed for Ang1 expression by
competitive RT-PCR as described in Materials
and Methods. The results are expressed as copy
numbers per 10,000 b-actin transcripts. Statistical
comparisons were performed using the Mann±
Whitney U test (A). Representative blots for
Ang1 (B) and b-actin (C) are shown. Competitor
copy numbers are presented as the number per mg
target total RNA.
Figure 3. Increased expression of Tie2 mRNA in involved
psoriasis skin. Total RNAs from involved and uninvolved skin samples
of 12 patients with psoriasis and seven healthy skin samples were
analyzed for Tie2 expression by competitive RT-PCR as described in
Materials and Methods. The results are expressed as copy numbers per
10,000 b-actin transcripts. Statistical comparisons were performed using
the Mann±Whitney U test (A). Representative blots for Tie2 (B) are
shown. Competitor copy numbers are presented as the number per mg
target total RNA.
Figure 2. Increased expression of Ang2 mRNA in involved
psoriasis skin. Total RNAs from involved and uninvolved skin samples
of 12 patients with psoriasis and seven healthy skin samples were
analyzed for Ang2 expression by competitive RT-PCR as described in
Materials and Methods. The results are expressed as copy numbers per
10,000 b-actin transcripts. Statistical comparisons were performed using
the Mann±Whitney U test (A). Representative blots for Ang2 (B) are
shown. Competitor copy numbers are presented as the number per mg
target total RNA.
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RESULTS
Increased expression of Ang1, Ang2, and Tie2 in involved
psoriasis skin To assess the potential role of Ang1, Ang2, and
Tie2 in psoriasis, we ®rst examined mRNA levels in biopsy
specimens of involved and uninvolved skin from 12 patients with
psoriasis and in seven normal skin specimens from healthy controls.
Amounts of Ang1 and Ang2 mRNA were quanti®ed by
competitive RT-PCR and were represented as a value per
10,000 b-actin transcripts. As shown in Fig 1, Ang1 mRNA
levels were signi®cantly higher in involved psoriasis skin than in
uninvolved skin and healthy skin samples. Copy numbers of Ang1
transcripts were 881 6 533 in involved skin, 72 6 24 in
uninvolved skin, and 48 6 22 in healthy skin. Ang2 mRNA was
also expressed at higher levels in involved psoriasis skin (Fig 2).
Copy numbers of Ang2 transcripts were 212 6 146 in involved
skin, 6.8 6 3.0 in uninvolved skin, and 4.8 6 2.2 in healthy skin.
Tie2 mRNA levels were signi®cantly increased in involved
psoriasis skin samples (Fig 3). Copy numbers of Tie2 transcripts
were 168 6 101 in involved skin, 28 6 11 in uninvolved skin, and
22 6 10 in healthy skin. To compare the expression of
angiopoietins and Tie2 in psoriasis with that in other
in¯ammatory skin diseases, we examined the expression of these
molecules in skin samples from chronic spongiotic dermatitis. Copy
numbers of Ang1, Ang2, and Tie2 transcripts in dermatitis were
58 6 46, 36 6 20, and 40 6 35, respectively. This showed that
mRNA levels of Ang1, Ang2, and Tie2 in involved psoriasis skin
were higher than those observed in dermatitis.
We also examined PECAM mRNA expression as a marker of
endothelial cell proliferation in psoriasis. As expected, PECAM
transcripts were signi®cantly increased in involved skin
(625 6 484) compared to uninvolved skin (157 6 76, p < 0.001)
and healthy skin (71 6 38, p < 0.01). As endothelial cells can
express most angiogenic regulators, we compensated Ang1 and
Ang2 mRNA levels with PECAM mRNA levels (i.e., as a value
per 100 PECAM transcripts) to exclude discrepancies in vascular
density. These analyses con®rmed that copy numbers of Ang1
transcripts were signi®cantly higher in involved psoriasis skin
(157 6 122) than in uninvolved (46 6 39, p < 0.001) and healthy
(36 6 30, p < 0.01) skin. Likewise, copy numbers of Ang2
transcripts were also higher in involved psoriasis skin (34 6 28)
than in uninvolved (4.4 6 3.9, p < 0.001) and healthy (3.6 6 3.1,
p < 0.01) skin. Thus, increases in Ang1 and Ang2 expression in
psoriasis were the result of speci®c upregulation rather than the
consequence of increased vascular density.
To investigate the recently proposed hypothesis that angiopoie-
tins can produce complementary effects on angiogenesis in the
presence of other angiogenic molecules (Maisonpierre et al, 1997;
Gale and Yancopoulos, 1999), we examined VEGF and bFGF
expression in psoriasis. VEGF and bFGF mRNAs were present at
signi®cantly higher levels in involved psoriasis skin compared to
uninvolved and healthy skin (Fig 4). Increased VEGF mRNA
levels were particularly noticeable, with copy numbers of
12,581 6 880 in involved psoriasis skin compared to 88 6 45 in
uninvolved skin and 85 6 35 in healthy skin. This suggests that
angiopoietins together with VEGF, bFGF, or both, are coordi-
nately expressed in psoriasis.
Localization of Ang1, Ang2, and Tie2 expression in
psoriatic skin To further evaluate the pathologic implications
of increased Ang1, Ang2, and Tie2 expression in psoriasis, we
examined the spatial distribution of these molecules in involved and
uninvolved specimens from psoriasis patients and in healthy skin
specimens using immunohistochemistry and in situ hybridization.
Basement membrane (type IV collagen) and PECAM staining
clearly showed vascular proliferation in the papillary dermis of
involved psoriasis skin compared to uninvolved skin or normal
healthy skin (Fig 5A±D). Ang1 staining was undetectable in
healthy and uninvolved psoriasis skin specimens but clearly
detected in the papillary dermis of involved skin (Fig 5E±H). In
involved psoriasis skin, Ang1 signals were found in stromal cells,
such as mononuclear in¯ammatory cells, dermal dendritic cells, or
®broblasts. Consistent with protein expression results, Ang1
mRNA signals were also detected in the papillary dermis of
involved psoriasis skin (Fig 5I±L). Neither Ang2 protein nor
mRNA were observed in healthy and uninvolved psoriasis skin
specimens but were clearly expressed in the papillary dermis of
involved skin (Fig 5M±T). Ang2 signals were observed in
endothelial cells. Tie2 was expressed by proliferating endothelial
cells in the papillary dermis as well as by endothelial cells in the
deep dermis in involved psoriasis skin (Fig 6A±C). Healthy and
uninvolved psoriasis skin vessels also showed Tie2 staining.
Preabsorption of primary antibodies with their respective
immunizing peptides resulted in no speci®c staining patterns (data
not shown).
As angiopoietins are believed to play a key role in the
recruitment of pericytes, we examined the expression of aSMA
to detect possible alterations of pericytes in psoriasis. Proliferating
vessels in the papillary dermis of involved skin showed aSMA
staining as well as larger vessels in the deep dermis in the same
specimens (Fig 6D±G). Increased numbers of aSMA-positive
vessels were found in the papillary dermis of involved skin
compared to uninvolved and healthy skin, but no differences in
staining intensities of each vessel were observed between skin
samples. These ®ndings suggest that pericytes are properly recruited
to proliferating vessels in psoriasis.
Figure 4. Increased expression of VEGF and bFGF mRNAs in
involved psoriasis skin. Total RNAs from involved and uninvolved
skin samples of 12 patients with psoriasis and seven healthy skin samples
were analyzed for VEGF and bFGF expression by competitive RT-PCR
as described in Materials and Methods. The results are expressed as copy
numbers per 10,000 b-actin transcripts. Statistical comparisons were
performed using the Mann±Whitney U test. (A) VEGF; (B) bFGF.
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Figure 5. Distribution of Ang1 and Ang2
expression in psoriasis. Type IV collagen
immunostaining in involved psoriasis skin (A) and
uninvolved skin (B) and PECAM immunostaining
in involved psoriasis skin (C) and healthy skin (D)
(DAB/hematoxylin). Involved psoriasis skin shows
vascular proliferation in the papillary dermis.
Immunohistochemistry for Ang1 in involved skin
(E, F), uninvolved skin (G), and healthy skin (H)
(Fast Red/hematoxylin). In situ hybridization for
Ang1 antisense probe in involved skin (I, J) and
uninvolved skin (K) and for Ang1 sense probe in
involved skin (L) (BCIP/NBT; no counterstain).
Ang1 protein and mRNA signals are observed on
cells in the papillary dermis of involved skin but
not in uninvolved skin or healthy skin.
Immunohistochemistry for Ang2 in involved skin
(M, N), uninvolved skin (O), and healthy skin (P)
(Fast Red/hematoxylin). In situ hybridization for
Ang2 antisense probe in involved skin (Q, R) and
uninvolved skin (S) and for Ang2 sense probe in
involved skin (T) (BCIP/NBT; no counterstain).
Ang2 protein and mRNA signals are observed on
endothelial cells (arrows) in the papillary dermis of
involved skin but not in uninvolved skin or
healthy skin. Sense probes for in situ hybridization
show no speci®c staining patterns (L, T).
Figure 6. Immunohistochemistry of Tie2,
aSMA, and VEGF. Tie2 staining in the
papillary dermis (A) and the deep dermis (B) of
involved psoriasis skin and healthy skin (C) (Fast
Red/hematoxylin). Proliferating vessels in the
papillary dermis of involved skin show positive
staining for Tie2 as well as vessels in the deep
dermis or in healthy skin. aSMA staining in the
papillary dermis (D, E) and the deep dermis (F) of
involved psoriasis skin and healthy skin (G)
(DAB/hematoxylin). Vessels in the papillary
dermis of involved skin show positive staining for
aSMA as well as vessels in the deep dermis or in
healthy skin. Arrowhead (F) shows an eccrine duct.
VEGF staining in involved psoriasis skin (H),
uninvolved skin (I), and healthy skin (J) (Fast
Red; no counterstain). VEGF staining was
observed in the proliferating epidermis of involved
skin and in some mononuclear in¯ammatory cells
in®ltrating the upper dermis. VEGF signals were
not detectable or only faintly detectable in
uninvolved skin and healthy skin.
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VEGF staining was abundantly observed in keratinocytes in
proliferating epidermis in involved skin, but signals were not
detectable or only faintly detectable in healthy skin or uninvolved
skin samples (Fig 6H±J). This suggests that angiopoietins are
expressed in the presence of high levels of VEGF.
Cytokine regulation of Ang1, Ang2, and Tie2 To identify
molecules that may regulate Ang1 and Ang2 expression, we
investigated the effects of various cytokines in HMVEC and dermal
®broblast cultures by quantitative RT-PCR. The cytokines were
chosen according to their ability to affect cell growth and
differentiation of endothelial cells or ®broblasts (Herrmann and
Bohme, 1993; Bouck et al, 1996). As shown in Fig 7, VEGF and
bFGF noticeably elevated Ang2 mRNA levels in HMVEC whereas
PDGF, bFGF, and TGF-b showed no or minor inhibitory effects
on Ang1 expression in ®broblast cultures. To more closely
determine the effects of VEGF and bFGF on Ang2 expression,
we performed northern blot and immunoblot analyses on HMVEC
cultures (Fig 8). VEGF and bFGF enhanced Ang2 mRNA levels
up to 6.2 6 1.2-fold (n = 4, p < 0.01) and 8.1 6 1.1-fold (n = 4,
p < 0.01), respectively. Both cytokines used in combination
showed an 11.4 6 2.8-fold increase (n = 4, p < 0.01). At the
protein level, VEGF upregulated Ang2 expression by 4.2 6 0.7-
fold (n = 4, p < 0.05), bFGF by 4.6 6 1.0-fold (n = 4, p < 0.05),
and VGEF and bFGF by 7.2 6 1.8-fold (n = 4, p < 0.05).
To evaluate the cytokine regulation of the Tie2 receptor, we
examined the effects of VEGF and bFGF in HMVEC by northern
blot and immunoblot analyses (Fig 9). VEGF and bFGF increased
Tie2 mRNA levels up to 3.0 6 0.5-fold (n = 4, p < 0.01) and
3.2 6 0.7-fold (n = 4, p < 0.01), respectively. Tie2 protein
expression was also increased 2.8 6 0.4-fold by VEGF (n = 4, p
< 0.05) and 3.0 6 0.8-fold by bFGF (n = 4, p < 0.05).
Ang1, Ang2, and Tie2 expression in psoriatic skin during
antipsoriatic treatment To determine whether an
improvement in skin lesions was correlated with changes in
angiopoietins and Tie2 expression, we examined mRNA levels of
these molecules in serial biopsies from psoriatic patients who had
undergone successful antipsoriatic therapy. Skin biopsies were
taken from skin lesions of ®ve psoriatic patients treated with PUVA
and two patients treated with topical tazarotene. All patients
showed marked clinical improvement during antipsoriatic therapy,
reaching minimal residual activity after 4±8 wk of treatment. After
8 wk of therapy, Ang1, Ang2, Tie2, and PECAM mRNA levels in
involved skin were signi®cantly reduced (Fig 10). The reduction
in Ang2 was particularly noticeable. Ang2 mRNA levels in
involved skin were reduced to levels observed in uninvolved skin
after 8 wk of therapy, whereas Ang1, Tie2, and PECAM
expression levels in clinically improved psoriasis lesions were still
higher compared to uninvolved skin. Moreover, in three patients
tested, marked reduction of Ang2 in involved skin was already
evident at week 4 of therapy.
Figure 7. Cytokine regulation of Ang1 and Ang2 mRNAs in cell
cultures. Cytokine treatments were performed as follows. For
®broblasts, incubation in serum-free DMEM with 50 ng per ml PDGF,
50 ng per ml bFGF, 50 ng per ml TGF-b1, or control (no factor added)
for 12 h; for HMVECs, incubation in 2.5% FBS supplemented EBM
with 50 ng per ml VEGF, 50 ng per ml bFGF, or control for 12 h.
After total RNA extraction, amounts of mRNAs in these cells were
estimated by competitive RT-PCR as described in Materials and Methods.
Values are presented as copy numbers per 10,000 b-actin transcripts and
expressed as mean 6 SD of quadruplicate cultures. *p < 0.01 vs control
by the two-sided Student's t test. (A) Ang1; (B) Ang2.
Figure 8. Effect of VEGF and bFGF on Ang2 expression in
HMVEC cultures. Subcon¯uent HMVECs were incubated in EBM
with 50 ng per ml VEGF, 50 ng per ml bFGF, or both for 12 h. (A)
After total RNA extraction, Ang2 mRNA expression was assessed by
northern blot analysis. (B) Aliquots of culture medium corresponding to
the same cell numbers (10,000 cells) were analyzed for Ang2 protein
expression by immunoblotting.
Figure 9. Effect of VEGF and bFGF on Tie2 expression in
HMVEC cultures. Subcon¯uent HMVECs were incubated in EBM
with 50 ng per ml VEGF or 50 ng per ml bFGF for 12 h. (A) After
total RNA extraction, Tie2 mRNA expression was assessed by northern
blot analysis. (B) Protein extracts of 5 mg prepared from these cells were
analyzed for Tie2 protein expression by immunoblotting.
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DISCUSSION
In this study, we have shown that the expression levels of Ang1,
Ang2, and its speci®c receptor, Tie2, were elevated in involved
psoriasis skin compared to uninvolved skin, healthy skin, and
chronic dermatitis skin. Angiopoietins and Tie2 receptor are
thought to play a key role in angiogenesis during embryogenesis.
This system has also been shown to participate in the development
of pathologic neovascularization, including tumor angiogenesis,
ocular vascular disease, and wound healing (Wong et al, 1997;
Peters et al, 1998; Stratmann et al, 1998; Otani et al, 1999; Zagzag et
al, 1999). Therefore, our results suggest that upregulation of
angiopoietins and Tie2 is closely associated with vascular expansion
in psoriasis.
Our histopathologic studies revealed the different localization of
Ang1 and Ang2 expression in psoriasis. Ang1 was expressed by
stromal cells in the highly vascularized papillary dermis of involved
skin. Ang2 was also present in the papillary dermis of involved
psoriasis skin, but the signals were limited to endothelial cells. The
distinct but overlapping expression pattern suggests that the
elevated expression of the two molecules may have different
implications for the development of vascular expansion in psoriasis.
Ang2 is thought to be a crucial initiator for angiogenesis in which
VEGF is involved. In the rat glioma model, Ang2 was highly
induced in co-opted host vessels around tumor cells immediately
before robust angiogenesis (Holash et al, 1999). These ®ndings
indicate that upregulation of Ang2 in endothelial cells could be an
initial sign of vascular expansion in psoriasis, as well as of tumor
angiogenesis. Moreover, a recent study revealed that Ang2
expression was downregulated by Ang2 itself in bovine micro-
vascular endothelial cell cultures (Mandriota and Pepper, 1998).
This suggests that, shortly after overproduction, Ang2 expression in
psoriasis lesions may be normalized via a negative feedback
mechanism. Thus, it is possible that, at the onset of neovasculariza-
tion in a psoriatic lesion, interaction between Ang1 and the Tie2
receptor is blocked by Ang2 upregulation, resulting in endothelial
cell destabilization and the initiation of vascular proliferation in the
presence of high VEGF levels. Subsequently, local diminution of
Ang2 with high expression of Ang1 would reestablish Tie2
signaling and maintain the newly formed proliferating vessels. As
Ang1 signaling is believed to participate in pericyte±endothelial cell
interactions, the upregulation of Ang1 may contribute to the
recruitment of pericytes to proliferating vessels in psoriasis.
Consistent with this hypothesis, our immunohistochemistry results
for aSMA showed that pericytes were neatly distributed in
proliferating vessels of involved psoriasis skin. In addition, Ang1
may also promote vascular expansion in the presence of high VEGF
levels in psoriasis, as studies have reported that Ang1 was able to
synergize with VEGF to induce neovascularization (Asahara et al,
1998) and sprout formation (Koblizek et al, 1998) and augment
antiapoptotic effects (Kwak et al, 1999; Papapetropoulos et al,
1999). As shown in Fig 11, alternate binding of Ang1 and Ang2 to
the Tie2 receptor may occur incessantly, maintaining vascular
expansion in an active psoriatic lesion.
Cytokine studies clearly demonstrated that both VEGF and
bFGF upregulated Ang2 expression in HMVEC cultures, which is
in general agreement with a previous report (Mandriota and
Pepper, 1998). In addition, our study showed that these two
growth factors synergistically enhanced the expression of Ang2.
Because VEGF and bFGF are present at high levels in involved
psoriasis skin, these growth factors may be involved in the
induction of Ang2 expression.
Tie2 was expressed by endothelial cells in the highly vascularized
papillary dermis as well as by endothelial cells in other areas
including the deep dermis. Because Tie2 receptor signaling is
assumed to have a role in the stabilization of newly formed vessels,
Tie2 receptor upregulation may be crucial for vascular expansion in
psoriasis and would re¯ect the increase in new vessels. Our study
also showed that VEGF and bFGF enhanced the expression of the
Tie2 receptor on endothelial cells, suggesting that VEGF and bFGF
are involved in the maintenance of proliferating vessels through the
upregulation of Tie2 receptor signals.
This study showed an association between improvement in skin
lesions as a result of antipsoriatic therapy and decreased levels of
angiopoietins and Tie2 in skin lesions. In particular, successful
antipsoriatic treatment dramatically reduced Ang2 expression in
involved skin to levels of uninvolved skin, and this reduction
Figure 10. Ang1, Ang2, and Tie2 expression
in psoriatic skin during antipsoriatic
treatment. Involved skin samples from ®ve
patients treated with PUVA (closed circles) and two
patients with tazarotene (closed rectangles) were
taken before therapy started (week 0) and during
therapy (weeks 4 and 8). Total RNAs from serial
biopsies were analyzed for gene expression by
competitive RT-PCR as described in Materials
and Methods. Measurement of uninvolved skin
before therapy (open circles or rectangles) is also
shown. Results are expressed as copy numbers per
10,000 b-actin transcripts. Changes in gene
expression after 8 wk of therapy compared to
before therapy were estimated by Wilcoxon
single-rank test. (A) Ang1; (B) Ang2; (C) Tie2;
(D) PECAM.
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appears to occur early during therapy. These observations suggest
that alteration of Ang2 expression levels may be particularly
important in controlling vascular proliferation in psoriasis. PUVA
and retinoid treatments have been shown to affect psoriatic
keratinocytes or activated T cells (Esgleyes-Ribot et al, 1994;
Vallat et al, 1994). Our studies suggest that suppression of Ang2
expression in endothelial cells of the papillary dermis is another
possible molecular basis for these antipsoriatic therapies.
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Figure 11. Altered expression of Ang1 and Ang2 in the
development and resolution of microvascular proliferation in
psoriasis. (A) Endothelial cells in uninvolved psoriasis skin. Proper
balance between Ang1 and Ang2 expression controls the integrity of
blood vessels through the Tie2 receptor in uninvolved skin, as well as in
healthy skin. (B) Ang2 expression in endothelial cells at the onset of
neovascularization in a psoriatic lesion. Local overproduction of Ang2 in
endothelial cells by VEGF and/or bFGF blocks the Ang1 signal, resulting
in endothelial cell destabilization and initiation of vascular proliferation in
the presence of other angiogenic inducers such as VEGF and/or bFGF.
(C) Papillary dermis of an active psoriatic lesion. Ang2 overexpression
may be downregulated via a negative feedback mechanism. Ang1
expressed by stromal cells may then reestablish Tie2 signaling and
maintain the newly formed proliferative vessels. Moreover, in some
endothelial cells, Ang2 may again increase and bind to Tie2 receptor by
overcoming high Ang1 levels, which promotes the recommencement of
neovascularization. Alternate binding of Ang1 and Ang2 to Tie2 may
maintain vascular expansion in the psoriatic lesion. (D) The papillary
dermis of a resolving psoriatic lesion. Successful antipsoriatic treatment
downregulates Ang2 expression and may stop the formation of new
vessels, thereby normalizing vessels in a psoriatic lesion.
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